Press Release

Dec 1, 2022
Cytox welcomes momentous and historic news for Alzheimer’s disease research – the dawn of a new therapeutic age?

Fantastic news from Eisai that their therapeutic agent, Lecanemab, has been shown to slow the damage to the brain caused by Alzheimer’s disease. According to Susan Kohlhaas, Director of Research at Alzheimer's Research UK, “this is the first time researchers have shown that cognitive decline with Alzheimer's can be slowed down”. The Cytox team salute dementia researchers worldwide for their persistence and look forward to a time when Alzheimer’s disease is treatable.

For those worried about Alzheimer’s disease, peace of mind comes from knowing their personal risk, which is partly due to genes and partly due to lifestyle and health. The Alzheimer’s Risk Test, powered by genoSCORE™, looks at an individual’s genes to find out if they have been born with a higher or lower risk than other people their age. Giving recipients the chance to plan for the future and make informed decisions about their health. All from a small saliva sample.

In a conversation with our CEO, Dr Richard Pither, about the breaking news from Eisai, Professor Sir John Hardy of University College, London said “Polygenic risk testing is able to be used at the earliest possible time to identify those most likely to benefit from future interventions, including lifestyle and environmental risk avoidance, management of co-morbidities and ultimately, use of disease-modifying drugs such as Lecanemab”.

Go to www.alzheimers-risk-test.com to find out more about getting tested.

Cytox looks forward to a time when Alzheimer’s disease is treatable.

About Cytox (www.cytoxgroup.com)
Cytox Group Limited aims to enable everyone to know their personal risk for Alzheimer’s disease. Cytox supports two products in the market, powered by its genoSCORE™ Polygenic Risk Scoring technology. In the US, Cytox has partnered with Sampled Smart Labs which has developed the Alzheimer’s Risk Test, powered by genoSCORE™ (www.alzheimers-risk-test.com). In Europe Cytox, with its partner Yourgene Health, markets genoSCORE-LAB (www.genoscore-lab.com).

About genoSCORE™
The genoSCORE™ technology is used to assess the genetic risk of cognitive decline due to Alzheimer’s disease (AD). The test, which uses a simple blood or saliva sample, analyses over 100,000 single nucleotide polymorphisms (SNPs) - small genetic variations - that are associated with AD. As such, the test generates a patient-specific polygenic risk score (PRS). Clinicians can use the test to assess patients for the risk of developing Alzheimer's, including before symptoms arise. In addition, the test can be used by developers of new AD drugs to identify individuals most likely to experience cognitive decline and/or respond to the therapy under investigation.

About Sampled and Sampled SMART Labs
Sampled is a next-generation laboratory that unlocks the valuable data in any biological sample to enable health innovators to improve human health. The integrated services offered by Sampled SMART Labs provide partners with a seamless solution for sample management and analysis. Sampled is headquartered in Piscataway, N.J. with labs across the US and Europe and partner labs in the Netherlands, China, and Australia. Infinity BiologiX LLC, Roylance Stability Storage Limited and Roylance Scientific Limited are doing business as Sampled. For more information, visit www.sampled.com.

About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops integrated genomic technologies and services enabling precision medicine. The group works in partnership with global leaders in DNA technology to advance diagnostic science. Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US, and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com.